

Francesca Ricci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997234/publications.pdf>

Version: 2024-02-01

39
papers

721
citations

516710

16
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

1732
citing authors

#	ARTICLE	IF	CITATIONS
1	Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210950.	3.2	0
2	Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin. <i>American Journal of Cancer Research</i> , 2021, 11, 2303-2311.	1.4	1
3	Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020, 12, 2398.	3.7	9
4	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. <i>Cancers</i> , 2020, 12, 3846.	3.7	5
5	Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism. <i>Free Radical Biology and Medicine</i> , 2020, 150, 125-135.	2.9	36
6	Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 572-580.	1.4	6
7	Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983954.	3.2	35
8	A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2018, 21, 50-56.	1.1	3
9	Recent Insights into Mucinous Ovarian Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1569.	4.1	43
10	Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib. , 2018, , .		1
11	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018, 9, 24707-24717.	1.8	14
12	Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. <i>Molecular Cancer</i> , 2017, 16, 97.	19.2	15
13	Heteronanoparticles by self-Assembly of Doxorubicin and Cycloamine Conjugates. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 953-957.	2.8	15
14	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. <i>BMC Cancer</i> , 2017, 17, 366.	2.6	16
15	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 6433-6445.	1.8	29
16	Patient-derived ovarian cancer xenografts re-growing after a cisplatin treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy. <i>Oncotarget</i> , 2017, 8, 7441-7451.	1.8	23
17	Abstract A40: Profile of DNA repair status in a recently established panel of patient-derived ovarian carcinoma xenografts. , 2017, , .		0
18	Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
19	Histone demethylating agents as potential <i>S</i> -adenosyl-methionine-competitors. <i>MedChemComm</i> , 2016, 7, 1245-1255.	3.4	5
20	4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 79-89.	5.5	24
21	Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes. <i>European Journal of Cancer</i> , 2016, 61, S46-S47.	2.8	0
22	Class II phosphoinositide 3-kinase C2 ¹² regulates a novel signaling pathway involved in breast cancer progression. <i>Oncotarget</i> , 2016, 7, 18325-18345.	1.8	25
23	Click Reaction as a Tool to Combine Pharmacophores: The Case of Vismodegib. <i>ChemPlusChem</i> , 2015, 80, 938-943.	2.8	19
24	Cyclopamine- ⁶⁴ Paclitaxel-Containing Nanoparticles: Internalization in Cells Detected by Confocal and Super-Resolution Microscopy. <i>ChemPlusChem</i> , 2015, 80, 1380-1383.	2.8	16
25	Abstract 4091: Investigations on the role of epithelial-mesenchymal transition and cancer stem cells in the response to therapy in patient-derived ovarian carcinoma xenografts. , 2015, , .		0
26	Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models. , 2015, , .		0
27	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. <i>Cancer Research</i> , 2014, 74, 6980-6990.	0.9	110
28	601: Cisplatin response in a panel of patient-derived ovarian carcinoma xenografts: roles of epithelial mesenchymal transition and DNA repair. <i>European Journal of Cancer</i> , 2014, 50, S145.	2.8	0
29	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. <i>European Journal of Medicinal Chemistry</i> , 2014, 85, 179-190.	5.5	34
30	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0
31	Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas. , 2014, , .		0
32	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. <i>Cancer Treatment Reviews</i> , 2013, 39, 561-568.	7.7	24
33	Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model. <i>PLoS ONE</i> , 2013, 8, e79101.	2.5	16
34	ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. <i>American Journal of Cancer Research</i> , 2013, 3, 221-9.	1.4	11
35	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. <i>Cell Cycle</i> , 2012, 11, 2507-2517.	2.6	110
36	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. <i>Cell Cycle</i> , 2012, 11, 1966-1976.	2.6	43

#	ARTICLE	IF	CITATIONS
37	767 Ovarian Carcinoma Xenografts â€™ Drug Response and Molecular Characterization. European Journal of Cancer, 2012, 48, S182.	2.8	0
38	Abstract 4699: A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity. , 2012, , .		0
39	Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations. European Journal of Cancer, 2011, 47, 1086-1094.	2.8	32